Takeda Seeks Manufacturing Partners for Dengue Fever Vaccine


Japanese pharmaceutical company Takeda Pharmaceutical is exploring dengue fever vaccine production in Indonesia. Investment Minister Bahlil Lahadalia revealed the plan during a meeting with Takeda Pharmaceutical Chief Executive Officer Christophe Weber at the World Economic Forum, Davos, Switzerland, on Jan 19. Bahlil said that Indonesia is a dengue fever endemic country that needs a vaccine to prevent the disease.

Bahlil appreciated Takeda's efforts to develop a dengue vaccine and its investment in Indonesia since 1971. "We encourage Takeda not only to import the vaccine but also produce it in Indonesia," Bahlil said. The Food and Drug Monitoring Agency (BPOM) has approved Takeda for using Tetravalent Dengue Vaccine (TAK-003) for dengue fever in people aged 6-45. The Investment Ministry will also bring together local partners with Takeda. Meanwhile, Weber said the company needs an appropriate local partner to produce a dengue vaccine in Indonesia.

Start your free trial.

If you would like to get a 30-day free unlimited access to all of our insights, please click “Start free trial” button below. If you already have an account, please login.

What do subscribers receive?

As a subscriber, you’ll receive daily insights, weekly business digests, and quarterly industrial reports.

What kind of pieces will i get?

In-depth reports on assumption and impact analysis, as well as update and trends mapping, written by our credible and experienced analysts.

And, there is something else…

Enjoy a 30-day free trial, on us. Feel free to contact us with any additional questions you have.